The treatment from Sarepta Therapeutics was approved Thursday for children ages 4 and 5 with Duchenne muscular dystrophy, a rare muscle-wasting disease that causes early death.
  • Mattol@discuss.tchncs.deEnglish
    1·
    1 year ago

    Interesting discussion in the article. Seems like it’s a pretty experimental therapy atm without any conclusive evidence that it works.